Episode Details

In this episode of On The Line, host Matt Gurney sits down with Reece Martin, transit and transportation expert and new media entrepreneur, for a conversation about infrastructure, public policy, and how an online passion project turned into a career.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge cancer immunotherapy research that they’re helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.  

A new treatment for your cancer has been approved. Can you get it? Maybe, maybe not. Canada isn’t just one health jurisdiction. At the federal level, Health Canada assesses the safety and efficacy of all drugs and therapies in the country, and in a year — sometimes less — they can approve one for sale in Canada. Once approved, — or sometimes while the assessment is happening— the drug's cost effectiveness is evaluated by Canada's Drug Agency.  

Then the ball goes to the provinces. They work together to negotiate prices with the drug maker, to confirm that it doesn't duplicate something they’re already stocking, and that its potential value justifies its cost. Only after that can it be provided by each province’s ministry of health. This process can take years. It’s one reason that Canadian innovations leave the country to be developed elsewhere, and why drug companies don’t always choose Canada initially to launch their products. In the U.S., they get FDA approval, set a price, and wait for the market to decide if the price is right. In Canada, Health Canada approves and lengthy negotiations start, with no revenue or guarantee of future approval.

Organizations like BioCanRx are willing to wait out the dry years because they're not-for-profit, but companies with shareholders might skip the Canadian market until they’re making big money elsewhere. This means Canadians have to wait on the system for drugs that could save them, and are saving people in other countries. We’ll talk more about these problems in the weeks to come. Stay tuned for more.

Martin explains how his fascination with transit and transportation grew into a successful YouTube channel, and how that work eventually made him a go-to commentator for conventional media on major infrastructure issues. They discuss the opportunities created by the new media landscape, the challenges of building an audience around complex policy topics, and why expertise can now emerge from outside traditional institutions.

From there, the conversation turns to Canada’s infrastructure record. Matt and Jen often joke that “Canada no build good,” and Martin largely agrees — but with important caveats. He explains where Canada consistently goes wrong, why projects take so long and cost so much, and how political incentives often work against good long-term planning.

This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.

That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.

The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.

At the same time, Martin argues that Canada has real infrastructure success stories that deserve more attention. Rather than assuming failure is inevitable, governments should study the jurisdictions that consistently deliver major projects on time and on budget, both at home and abroad. If Canada can learn those lessons — and avoid the